Abstract 432P
Background
Although extravasation (EV) is an established complication of parenteral chemotherapy, it often goes under-documented and underestimated. The incidence and severity of extravasation can be influenced by patient, drug or procedure related factors. An understanding of the risk factors and predictors promotes precaution during chemotherapy.
Methods
A prospective study was conducted for one year in patients satisfying study criteria. Patient information such as demographics, history, disease, treatment regimen and EV related information was documented. Severity of EV was established using CTCAE 4.3. The captured data was subjected to appropriate statistical analysis using SPSS ver. 20.
Results
Amongst the 217 patients reviewed 46(21.20%) experienced EV [Grade 2(67.39%) and Grade 3(32.61%)]. Cluster statistics revealed age, gender and ambulation to be the most important predictors. Ambulation caused an 8 fold increase in the risk of EV (p < 0.001, [2.01-14.2]). Females were observed to be 2.5 times susceptible to EV (p = 0.001, [2.5-5.9]) than males. Progressive age i.e. beyond 60 years the risk of EV increases 2.02 times (p = 0.005, [1.3-3.8]). Additionally, age (p = 0.007, OR: 2.24 [1.22-6.71]), sex (p = 0.010, OR: 2.71 [1.38-7.64]), ambulation (p = 0.001, OR: 4.67 [2.09-4.90], co-morbidities (p = 0.029, OR: 3 [2.17-5.67] and the use of irritants (p = 0.007, OR: 2.25 [1.27-3.76] increased the risk of the patient getting severe EV injury.
Conclusions
Patient, drug and procedure related risk factors influence the incidence of chemotherapy induced EV injury. In the studied population, age, gender, ambulation and co-morbidities were established as predictors of extravasation. Multi-disciplinary approach and patient counselling can contribute to minimizing the discomfort and complication of EV.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
All Authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
465P - A phase IIIb open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: Exploratory biomarker analysis
Presenter: Jie Wang
Session: Poster display session
Resources:
Abstract
470P - Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review
Presenter: Rogelio Velasco
Session: Poster display session
Resources:
Abstract
471P - Chemotherapy in advanced thymic malignancies
Presenter: Ankur Varshney
Session: Poster display session
Resources:
Abstract
466P - Cancer immunotherapy efficacy and patients’ age: A systematic review and meta-analysis
Presenter: Yu Jiang
Session: Poster display session
Resources:
Abstract
506P - Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC)
Presenter: Jeffrey Ward
Session: Poster display session
Resources:
Abstract
480P - Safety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050
Presenter: Tony S.K. Mok
Session: Poster display session
Resources:
Abstract
503P - Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials
Presenter: Antonio Passaro
Session: Poster display session
Resources:
Abstract
488P - Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial)
Presenter: Kei Kusaka
Session: Poster display session
Resources:
Abstract
495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
Presenter: Anna Buder
Session: Poster display session
Resources:
Abstract
520P - A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
Presenter: Akito Hata
Session: Poster display session
Resources:
Abstract